Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by itchy, painful, and dry skin. Despite the great number of available therapies, economic evaluations are needed to provide evidence on their cost-efficiency to assist the National Health System (NHS) in decision-making. The objective of this study is to evaluate the cost-effectiveness of abrocitinib (200mg) versus dupilumab (300mg), tralokinumab (300mg), baricitinib (2mg/4mg) and upadacitinib (15mg/30mg) in the treatment of adult patients with severe AD who are candidates for systemic treatments from the Spanish NHS perspective.
This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.